Archive for the ‘biotech/medical’ category: Page 2438
Sep 7, 2016
How robots, drones and artificial intelligence will change everything
Posted by Klaus Baldauf in categories: biotech/medical, drones, economics, food, media & arts, robotics/AI, virtual reality
Silicon Valley, or the Greater Bay Area, is the 18th largest economy in the world, more than half the size of Canada’s economy and bigger than Switzerland, Saudi Arabia or Turkey. This is because the region has become the world leader in research and development of emerging technologies such as artificial intelligence, robotics, software and virtual reality.
“Software is eating the world,” said Silicon Valley investor Marc Andreessen famously in 2011. It was controversial but prescient.
Five years later, software-driven machines and drones perform surgery, write news stories, compose music, translate, analyze, wage war, guard, listen, speak and entertain. The world’s biggest box office hits — animated films such as “Frozen” or special effects in Hollywood blockbusters like “Star Wars” — are made using software.
Continue reading “How robots, drones and artificial intelligence will change everything” »
Sep 6, 2016
New Drug Clears Abnormal Brain Proteins Tied to Alzheimer’s
Posted by Dan Kummer in categories: biotech/medical, neuroscience
In people with Alzheimer’s disease, a new investigational drug can dramatically reduce the amount of amyloid beta plaque, the tangled clumps of proteins that form in the brains of Alzheimer’s patients, according to a new early study of the drug.
The drug works by spurring the immune system to recognize and clear the plaques.
“We believe that’s a hint of efficacy,” study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen, said during a news briefing. “We believe that needs to be confirmed with further studies.” Biogen is the Cambridge, Massachusetts, company that funded the trial and applied to patent the drug. [10 Things You Didn’t Know About the Brain].
Continue reading “New Drug Clears Abnormal Brain Proteins Tied to Alzheimer’s” »
Sep 6, 2016
Stem Cells Allow Scientists to Repair Injured Spinal Cords
Posted by Shailesh Prasad in categories: biotech/medical, neuroscience
In a study published in Nature Medicine, researchers report that they have successfully coaxed stem cell-derived neurons to regenerate lost tissue in damaged corticospinal tracts of rats.
Stem cells are an amazing part of medical research. Because of their ability to become virtually any cell in the human body, they could hold the cure for many varied and grave diseases—from bones, to sight, to memory and thinking, stem cells could help us correct a host of conditions.
In fact, it seems that stem cells might be the key to repairing spinal cord injuries.
Continue reading “Stem Cells Allow Scientists to Repair Injured Spinal Cords” »
Sep 6, 2016
THIS is how you can use ultrasound for wound healing
Posted by Shailesh Prasad in categories: biotech/medical, neuroscience
https://youtube.com/watch?v=PL-0Ga9Sziw
Other than speeding up bone healing, slowing Alzheimer’s in mice, ultrasound has been found to help with speedy wound healing. Ultrasound application can help diabetic patients, who suffer from helping defects, up to 30% to decrease the healing time of wounds.
![84197338_thinkstockphotos-178438513](https://lifeboat.com/blog.images/this-is-how-you-can-use-ultrasound-for-wound-healing.jpg)
Continue reading “THIS is how you can use ultrasound for wound healing” »
Sep 6, 2016
Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant
Posted by Steve Hill in categories: biotech/medical, engineering, genetics, life extension
The SENS Research Foundation has finally published this anticipated and important paper on mitochondrial gene transfer which has ramifications for mitochondrial diseases and more importantly one of the processes of aging. It is great to see that finally after a decade of criticism Aubrey de Grey has proven his approach is viable.
We explore the possibility of re-engineering mitochondrial genes and expressing them from the nucleus as an approach to rescue defects arising from mitochondrial DNA mutations. We have used a patient cybrid cell line with a single point mutation in the overlap region of the ATP8 and ATP6 genes of the human mitochondrial genome. These cells are null for the ATP8 protein, have significantly lowered ATP6 protein levels and no Complex V function. Nuclear expression of only the ATP8 gene with the ATP5G1 mitochondrial targeting sequence appended restored viability on Krebs cycle substrates and ATP synthesis capabilities but, failed to restore ATP hydrolysis and was insensitive to various inhibitors of oxidative phosphorylation. Co-expressing both ATP8 and ATP6 genes under similar conditions resulted in stable protein expression leading to successful integration into Complex V of the oxidative phosphorylation machinery. Tests for ATP hydrolysis / synthesis, oxygen consumption, glycolytic metabolism and viability all indicate a significant functional rescue of the mutant phenotype (including re-assembly of Complex V) following stable co-expression of ATP8 and ATP6. Thus, we report the stable allotopic expression, import and function of two mitochondria encoded genes, ATP8 and ATP6, resulting in simultaneous rescue of the loss of both mitochondrial proteins.
Sep 6, 2016
Entering the Final Days of the SENS Universal Cancer Treatment Fundraiser
Posted by Steve Hill in categories: biotech/medical, economics, life extension
For cancer research, meanwhile, the situation is more akin to an economic revolution, or disruptive advance in technology. Because all cancers must lengthen their telomeres, and because telomere lengthening is governed by a small number of processes, there is the opportunity to change the focus of cancer research from an endless procession of expensive new therapies, each targeting a tiny number of the hundreds of subtypes of cancer, to one single therapy that can effectively suppress all cancers.
The last few days have arrived for this year’s SENS Research Foundation crowdfunding campaign, focused on important groundwork to establish a universal therapy for all types of cancer. There are still a few thousand dollars left in the matching fund, so donations are still being matched. Cancer is just as much a part of aging that must be ended, brought completely under control, as all of the other line items in the SENS rejuvenation research portfolio, and this year is the first time that the SENS Research Foundation has run a fundraiser for this program.
Hopefully there is no need to remind the audience here that the SENS Research Foundation, and important ally the Methuselah Foundation, have in recent years achieved great progress in the field of rejuvenation research on the basis of our donations and our support. Some of the high points you’ll find mentioned here and there at Fight Aging!: support and ongoing expansion of the mitochondrial repair technologies now under development at Gensight; seed funding Oisin Biotechnologies for senescent cell clearance; unblocking efforts to clear glucosepane cross-links that stiffen tissues; running the lauded Rejuvenation Biotechnology conferences; and many more. If only all charities produced as great an impact with as few resources — and if only we were further along in the bootstrapping of an industry focused on the development of rejuvenation therapies.
Continue reading “Entering the Final Days of the SENS Universal Cancer Treatment Fundraiser” »
Wound-closure technologies are becoming less painful and more efficient at closing wounds.
Sep 5, 2016
Researchers Have A Vision: Cure Blindness
Posted by Shailesh Prasad in categories: biotech/medical, neuroscience
The government’s National Eye Institute is committing $12.4 million to research technologies that can regenerate damaged neurons.
Sep 5, 2016
A Look at IBM’s Watson 5 Years After Its Breathtaking Jeopardy Debut
Posted by Elmar Arunov in categories: biotech/medical, computing, robotics/AI
The year was 2012, and IBM’s AI software Watson was in the midst of its heyday.
Watson beat two of Jeopardy’s all-time champions a year earlier in 2011, and the world was stunned. It was the first widespread and successful demonstration of a natural language processing computer of its class. Combined with the popularity of Jeopardy, Watson became an immediate mainstream icon.
Later in 2012, IBM announced one of the first major practical partnerships for Watson—a Cleveland Clinic collaboration to bring the system into medical training.
Continue reading “A Look at IBM’s Watson 5 Years After Its Breathtaking Jeopardy Debut” »